Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cysteinyl leukotriene receptor type 1 is a key mediator linking lipid inflammatory signals to cellular responses central to allergy/asthma pathogenesis. Its pharmacological blockade forms a mainstay therapy for these conditions but with variable patient response profiles. Structurally distinct among GPCRs due to its unique disulfide bonding pattern between transmembrane domains—and functionally regulated by cytokines—it remains an active area for drug development targeting both respiratory diseases and broader inflammatory disorders.
Selective CysLT1R antagonism
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cysteinyl Leukotriene Receptor Type 1 (CysLT1R).